CytomX Therapeutics, Inc. (FRA:6C1)
Germany · Delayed Price · Currency is EUR | Market Cap | 590.80M +105.9% |
| Revenue (ttm) | 30.83M -75.9% |
| Net Income | -53.90M |
| EPS | -0.34 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 2.684 |
| Previous Close | 2.882 |
| Day's Range | 2.684 - 2.820 |
| 52-Week Range | 1.466 - 6.970 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About CytomX Therapeutics
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclin... [Read more]
News
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -
CytomX Therapeutics to Present at Upcoming June Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that managem...
CytomX Therapeutics initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of CytomX Therapeutics (CTMX) with an Outperform rating and $6 price target The company owns the only “de-risked” epithelial cell adhesion molecule antibody-drug conj...
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointm...
CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $17 and keeps a Buy rating on the shares. The firm cites the company’s financing-related dilution…
CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)
Reports Q1 revenue $10.26M, consensus $4.68M. “CytomX has continued to gain tremendous momentum in 2026 and we remain highly focused on executing against the multiple layers of potential value creatio...
CytomX Therapeutics Earnings Call Transcript: Q1 2026
Strong clinical progress for Varseta-M in late-line CRC, robust cash position, and focused capital allocation support advancement into pivotal studies. Next major data update expected in the second half of 2026, with expansion into new indications and combinations underway.
CytomX Therapeutics Quarterly report: Q1 2026
CytomX Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
CytomX Therapeutics Earnings release: Q1 2026
CytomX Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
CytomX Therapeutics Slides: Q1 2026
CytomX Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in ...
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wi...
CytomX Therapeutics Proxy statement: Proxy filing
CytomX Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
CytomX Therapeutics Proxy statement: Proxy filing
CytomX Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
CytomX Therapeutics Proxy statement: Proxy filing
CytomX Therapeutics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
CytomX Therapeutics participates in a conference call with JPMorgan
JPMorgan holds a conference call to address the Top-10 questions with management on April 13 at 11:30 am. Webcast Link
CytomX Therapeutics price target raised to $12 from $10 at Piper Sandler
Piper Sandler raised the firm’s price target on CytomX Therapeutics (CTMX) to $12 from $10 and keeps an Overweight rating on the shares. Updated Phase I data on varsetatug maseatecan…
CytomX Therapeutics price target raised to $16 from $10 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $16 from $10 and keeps an Overweight rating on the shares. The firm believes the CX-2051…
CytomX Therapeutics price target raised to $16 from $8 at Jefferies
Jefferies raised the firm’s price target on CytomX Therapeutics (CTMX) to $16 from $8 and keeps a Buy rating on the shares following the “impressive” Phase 1 Varseta-M data update…
CytomX Therapeutics price target raised to $15 from $10 at Guggenheim
Guggenheim raised the firm’s price target on CytomX Therapeutics (CTMX) to $15 from $10 and keeps a Buy rating on the shares. The firm, which is updating its model and…
CytomX Therapeutics 45.9M share Secondary priced at $5.30
Jefferies, Piper Sandler, Cantor Fitzgerald and Barclays acted as joint book running managers for the offering.
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing...
CytomX Therapeutics price target raised to $11 from $6 at Wedbush
Wedbush raised the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $6 and keeps an Outperform rating on the shares. The firm notes the company announced updated expansion…
CytomX Therapeutics announces $250M common stock offering
CytomX Therapeutics (CTMX) announced that it has commenced an underwritten public offering of $250M of shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants.
CytomX Therapeutics files automatic mixed securities shelf
16:03 EDT CytomX Therapeutics (CTMX) files automatic mixed securities shelf